CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Enlivex Therapeutics Ltd. (ENLV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Enlivex Therapeutics Ltd. (ENLV)

Finance Services · market cap $11M · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-02-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Enlivex Therapeutics Ltd. (ENLV) is a small-cap Israeli pharmaceutical company with 34 employees and a ~$150M market cap, developing Allocetra, a cell-therapy platform in Phase 2 for knee osteoarthritis and, under the OTS formulation, for sepsis. The next major scheduled catalyst is an estimated February 2026 Phase 2 data readout for the osteoarthritis program, rated 7/10 importance by CatalystAlert.
The catalyst path
  • 2027-02-15 (est.)Phase 2 · Allocetraimp 7/10
Pipeline
AssetPhaseIndication
AllocetraPhase 2Osteoarthritis, Knee
Allocetra-OTSPhase 2Sepsis
Price & technical context
3-month
-30.9%
6-month
-90.0%
12-month
-92.9%
52-wk range
$0.17–$18.15
vs 50-day MA
+20.5%
vs 200-day MA
-86.8%
Realized vol
297.5%
Max drawdown
-99.9%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ENLV (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.